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Contrast agents are non-biologically active substances required for various diagnostic imaging 
procedures. Exposure to contrast materials, predispose some patients to renal disturbances entitled 
as contrast-associated acute kidney injury. Nephropathy of contrast medium is a deterioration of 
renal function which happens within 24 to 72 hours after iodinated contrast medium injection. 
Cancer individuals have several risk factors for contrast-associated acute renal failure, consisting of 
administration of chemotherapy regimen, which are mainly nephrotoxic, presence of diabetes or 
chronic renal failure, hypertension, taking of non-steroidal anti-inflammatory drugs, simultaneous 
use of nephrotoxic drugs, aminoglycosides, cisplatin, cyclosporine A or amphotericin B, increases 
the risk of contrast-associated acute renal failure. Similarly, age more than 65 years old and anemia 
is an independent risk factor for contrast-associated acute kidney injury and also timing of CT 
within 45 days after last chemotherapy and low fluid intake, as the common risk factors in cancer 
individuals.
ABSTRACT
Implication for health policy/practice/research/medical education:
Chemotherapy regimen dose adjustment is indispensable for cancer individuals. Accordingly, evaluation of kidney function is crucial when 
Administrating intravascular contrast agents for computed tomography examinations of cancer individuals. Therefore, it is important to 
keep in mind that why individuals with malignancy are at somewhat higher risk of contrast nephropathy than the general population.
Please cite this paper as: Dayani MA, Mirzazadeh A. Prevention of contrast-associated acute kidney injury in cancer patients undergoing 
radiologic investigation using contrast media; a short-review to current knowledge. J Nephropathol. 2019;8(4):e43. DOI: 10.15171/
jnp.2019.43.
Introduction 
Contrast agents are non-biologically active substances 
required for various diagnostic imaging procedures. 
Exposure to contrast materials, predispose some patients 
to renal disturbances entitled as contrast-associated acute 
kidney injury (1-3). Nephropathy of contrast medium is 
a deterioration of renal function which happens within 
24 to 72 hours after iodinated contrast medium injection. 
Imaging is frequently used in hospitals and outpatient 
settings detection and for therapeutic interventions (4-
6). Contrast-induced acute kidney injury is associated 
with poor clinical outcomes and increased short-term 
and long-term mortality, the need for renal replacement 
therapy and prolonged hospital admission, and also an 
increase in cardiovascular disease (7,8). This complication 
is one of the most known forms of acute renal damage 
due to its possibility for prevention. However, the risk of 
acute renal failure following contrast medium injection 
is overemphasized, since such investigations are critical 
in cancer patients. This condition causes decreases 
prescription of the imaging studies in these patients, 
presumably due to the concern on prompting acute renal 
failure, leading to delay in detection of malignancy or 
its development. Hence, the administration of contrast 
agents should be balanced to risk/benefit calculation, in 
cancer patients (9-12).
Materials and Methods
For this short-review, we applied for some of sources 
including PubMed, Web of Science Embase, EBSCO, 
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Scopus and directory of open access journals (DOAJ). 
The search was directed toward using combinations of the 
following key words and/or their equivalents; contrast-
associated acute kidney injury, malignancy, contrast 
medium, vasoconstriction, renal medulla, acute kidney 
injury, oxidative stress, vacuolization, mitochondria, 
contrast agents, contrast-induced acute kidney injury, 
cancer and post-contrast acute kidney injury.
Pathophysiology of contrast-associated acute kidney 
injury
Pathophysiological viewpoint, iodinated contrast material 
stimulates vasoconstriction and also inflammation in this 
vulnerable vascular bed of renal medullary region leading 
to the creation of reactive oxygen species. Additionally, the 
exposure to contrast medium, decreases oxygen pressure 
in the deep renal medulla and simultaneously induces 
an increase in ion transport and oxygen utilization at 
the TAL (thick ascending limb) (13-16). Accordingly, an 
increase in tubular pressure causes tubular obstruction 
which results in an enhanced oxygen consumption and 
worsening of ischemic damage (12-17). On the other 
hand, vasoconstriction imposes the oxidative damage 
which further intensifies the hypoxia in renal medullae, 
since the combined effects of low oxygen delivery due 
to vasoconstriction and high oxygen consumption in 
the proximal tubules render the renal medullae mainly 
vulnerable to hypoxic damage. Therefore, two main 
mechanisms are interacted, direct tubular cytotoxicity 
and kidney ischemia (18-20). Contrast materials provoke 
kidney vasoconstriction through intensifying the release 
of adenosine and endothelin from kidney cells. These 
substances also strengthen the creation and release of 
reactive oxygen species, which may result in direct cytotoxic 
consequences on kidney tubular cells. Additionally, 
hemodynamic instability, have been suggested (12-19).
The direct toxicity of contrast agents to renal tubular 
epithelial cells, leading to apoptosis and necrosis 
and resultant loss of function. Accordingly, indirect 
mechanisms are associated with ischemic injury due 
to renal vasomotor alteration implicated by vasoactive 
agents like nitric oxide, prostaglandins and endothelin, 
since following a diminution in nitric oxide creation, the 
ischemia will increase and will lead to nephrotoxicity (20-
23). Numerous studies showed the value of endothelin, 
which has been detected to increase after contrast 
media exposure (24). The attentions are also toward 
the role of adenosine in inducing contrast-associated 
acute kidney injury, while intra-renal injected adenosine 
makes hemodynamic disturbances similar to contrast 
nephropathy (25,26).
Likewise, the direct cytotoxicity is conducted by 
vacuolization or osmotic necrosis which promotes 
apoptosis in renal tubular cells when they resorb/adsorb 
iodinated contrast medium (27). 
In summary iodinated radiocontrast material perturbs 
proximal renal tubule epithelium by alteration of cellular 
morphology (vacuolization), increasing the oxidative 
stress (enhanced creation of reactive oxygen species), 
decreased efficacy of the electron transport chain and ATP 
production due to mitochondrial dysfunction, cut activity 
of cell survival kinases (28-31).
Acute kidney insufficiency in individuals with 
malignancy
The incidence of acute kidney injury fluctuates in cancer 
patients. Several factors are responsible for acute renal failure 
including stage and type of underlying of malignancy, 
presence of metastasis, critical illness, infections and fluid 
intake (32). Most of chemotherapeutic drugs are excreted 
by the kidney. Conversely acute renal failure, by altering 
the pharmacokinetic of these drugs might lead to toxic 
concentration (32). Accordingly, when acute kidney 
injury requiring dialysis, chemotherapeutic drug level 
may fluctuate and result in sub-therapeutic levels and 
potentially could lead to unsuccessful cancer treatment. 
In addition, simultaneous antibiotic administration or 
narcotics, may aggravate acute kidney injury of cancer 
patients (33-35).
Post-contrast acute kidney injury in cancer individuals
Unfortunately, contrast-related acute renal failure is 
the third most common cause of hospital-acquired 
kidney damage, assuming for 12% of cases (17,36). 
Conventionally, contrast nephropathy is defined as an 
increase in the plasma creatinine concentration of at least 
0.5 mg per deciliter or as a minimum of 25% increase 
from the baseline value within two to five days following 
administration of contrast agent (37). The intensity of 
this dysfunction can differ from a mild increase in plasma 
creatinine to long-lasting kidney injury requiring dialysis 
(38,39). In general, the incidence of contrast-associated 
acute kidney injury is low, less than two percent, in 
individuals with normal to slightly diminished kidney 
function (GFR more than 60 ml/min per 1.73 m2) 
(40,41). In contrast, in individuals with moderate to severe 
renal failure the frequency is high and is around 55% (42). 
Cancer patients have various risk factors for contrast-
associated acute kidney injury like age more than 65 
years and anemia are the independent risk factors (43-
47). Additionally, timing of CT within 45 days after last 
chemotherapy and low-fluid intake, are other risk factors. 
Of predisposing factors mentioned above, however pre-
existing kidney failure is the utmost important risk factor 
for contrast-associated acute kidney injury. Accordingly, 
the highest risk of contrast-induced nephropathy is in 
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patients with both diabetes and pre-existing kidney 
failure (48,49). Similarly, the type of chemotherapy and 
the timing of treatment and CT scanning are other risk 
factors for acute reactions to iodinated contrast material. 
Irrespective of the cause of acute kidney injury by contrast 
agents, cancer individuals who are complicated by contrast 
nephropathy may have worse survival and prognosis (50). 
In a study on 2,240 patients with malignancy, glomerular 
filtration rate below 45 mL/min/1.73 m2 who underwent 
contrast-enhanced computed tomography with contrast-
induced nephropathy preventive modalities Jeon et al, 
found, the global incidence of contrast nephropathy was 
2.5%. They found that diabetes mellitus, glomerular 
filtration rate and plasma albumin value were independent 
predictors of contrast nephropathy (51,52). 
Recently, Hong et al conducted a retrospective study 
on 820 cancer individuals to assess the frequency and 
possible predictors of contrast-associated acute kidney 
injury in cancer patients without chronic renal failure who 
underwent contrast-enhanced computed tomography. 
They detected, the incidence of contrast-associated acute 
kidney injury was 8.0%. Additionally, they found BUN/
creatinine more than 20, serial CT examination, liver 
cirrhosis and hypotension, are associated with post-contrast 
acute kidney injury as the predisposing parameters. They 
concluded, baseline plasma creatinine below1.5 mg/dL, is 
a risk for contrast-induced nephropathy (51). 
Notably, cancer patients experience repeated imaging 
examinations. Malignancy staging and estimation of 
treatment response commonly necessitate injection of 
intravascular contrast medium to conduct computed 
tomography examinations. Some of these patients 
require multiple contrast-enhanced materials during the 
treatment schedule (53,54), thereby increases the risk 
of contrast-induced nephrotoxicity, predominantly in 
individuals with previous disturbed kidney function or 
diabetes (48). Some investigations have determined the 
presence of kidney insufficiency in individuals with solid 
tumors. Conversely, an increased incidence of cancer has 
been described in individuals with chronic kidney failure 
(55,56). 
Therefore, chemotherapy regimen dose adjustments 
are indispensable for cancer individuals. Accordingly, 
evaluation of kidney function is crucial when there is 
a necessity to administration of intravascular contrast 
agents for computed tomography examinations of cancer 
individuals (48). 
Overall, patients with cancer are at risk of acute kidney 
injury by sepsis, primary thrombotic microangiopathies, 
direct involvement of the kidney by hematological 
malignancies or tumor infiltration or propagation and 
various metabolic disturbances and also antineoplastic 
treatments (57). Acute kidney injury is a significant cause 
of mortality and morbidity in patients with malignancy. 
Moreover, the presence of acute kidney injury may have 
an extremely negative influence on oncological regimen.
Conclusion
A life-threatening side effect of exposure to contrast media 
is post-contrast acute renal failure, which is detected as a 
deterioration of kidney function arising 48 to 72 hours 
after injection. The frequency of kidney failure amongst 
patients with cancer is high since a majority of them are 
on simultaneous nephrotoxic chemotherapeutic regimen. 
Similarly, most of cancer patients are old with poor 
appetite, nausea and vomiting which predispose them 
to dehydration and aggravation of acute kidney injury 
more. Therefore, it is not hard to identify why individuals 
with malignancy are at slightly higher risk of contrast 
nephropathy than the general population.
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